1.5 Abstract in Rivista

1.5 Abstract in Rivista: [1822] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 501 a 520 di 1.822

Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A phase II study

2007-01-01 Chiesa, Md; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Lazzarelli, S; Brighenti, M; Passalacqua, R

Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial

2013-01-01 Caffo, O; Sava, T; Basso, U; Buti, S; Lo Re, G; Sacco, C; Lodde, M; Facchini, G; Zustovich, F; Perin, A; Russo, L; Veccia, A; Galligioni, E

Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): update of a phase II study

2010-01-01 Dalla Chiesa, M; Poli, R; Tomasello, G; Lazzarelli, S; Brighenti, M; Negri, F; Curti, A; Auzzani, A; Buti, S; Liguigli, W; Passalacqua, R

Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab

2018-01-01 Mazzaschi, G; Facchinetti, F; Madeddu, D; Buti, S; Gelsomino, F; Ardizzoni, A; Aversa, F; Missale, G; Quaini, F; Tiseo, M

High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with Oxaliplatin, Folinic Acid (FA), 5-Fluorouracil (5-FU) and Irinotecan (COFFI) in metastatic gastric cancer (MGC)

2008-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Brighenti, M; Lazzarelli, S; Auzzani, A; Curti, A; Martinotti, M; Passalacqua, R

A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): A pilot study

2012-01-01 Buti, S; Donini, M; Lazzarelli, S; Brighenti, M; Passalacqua, R

Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)

2017-01-01 Procopio, G; Prisciandaro, M; Iacovelli, R; Mancini, M; Fornarini, G; Facchini, G; Carteni, G; Napolitano, M; Sternberg, Cn; Caserta, C; Bregni, M; Massari, F; Buti, S; Biasco, E; De Giorgi, U; Zustovich, F; Ratta, R; Ortega, C; Tortora, G; Verzoni, E

Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A feasibility study

2006-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Lazzarelli, S; Brighenti, M; Donati, G; Cattaneo, M; Passalacqua, R

Gefitinib plus interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)

2005-01-01 Buti, S; Chiesa, Md; Tomasello, G; Negri, F; Machiavelli, A; Bosio, G; Stifani, I; Betti, M; Buononato, M; Passalacqua, R

LOH as “the missing instability” potentially underlying the tumor immunogenicity: on the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer

2017-01-01 Bersanelli, M; Gnetti, L; Azzoni, C; Bottarelli, L; Gasparro, D; Leonardi, F; Silini, Em; Buti, S

Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)

2015-01-01 Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; Di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G

Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)

2007-01-01 Passalacqua, R; Buzio, C; Buti, S; Labianca, R; Porta, C; Boni, C; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Caminiti, C

Relationship between enzalutamide activity and previous antiandrogen withdrawal syndrome (AWS) in patients with metastatic castration-resistant prostate cancer (MCRPC)

2015-01-01 Alesini, D; Sisani, M; Altavilla, A; Procopio, G; Hamzaj, A; Grillone, F; Massari, F; Marrocolo, F; Zaniboni, A; Mattioli, R; Buti, S; Battaglia, M; Caffo, O; De Angelis, V; Bracarda, S

Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient's counselling preliminary analysis of the INVIDIa study

2017-01-01 Bersanelli, M; Castrignanò, P; Gambale, E; Cortellini, A; Tiseo, M; Natoli, C; Ficorella, C; Panni, S; Rossetti, S; Papa, A; Mazzoni, F; Facchini, G; De Giorgi, U; Procopio, G; Atzori, F; Sava, T; De Luca, E; Maestri, A; Massari, F; Buti, S

Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)

2017-01-01 Bracarda, S; Galli, L; Maruzzo, M; Lo Re, G; Buti, S; Favaretto, A; Costanzo, Fd; Sacco, C; Merlano, M; Mucciarini, C; Zafarana, E; Romito, S; Maestri, A; Giorgio, Cg; Ionta, Mt; Turci, D; De Giorgi, U; Procopio, G; Cortesi, E; Porta, C

Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets

2009-01-01 Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Dalla Chiesa, M; Tomasello, G; Negri, F; Lazzarelli, S

Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials

2013-01-01 Caffo, O; Sava, T; Zustovich, F; Lodde, M; Sacco, C; Lo Re, G; Buti, S; Basso, U; Gamucci, T; Facchini, G; Perin, A; Segati, R; Russo, L; Veccia, A; Galligioni, E

Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)

2008-01-01 Passalacqua, R; Buti, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Lazzarelli, S

Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors

2017-01-01 Bersanelli, M; Vaglio, A; Sverzellati, N; Galetti, M; Incerti, M; Parziale, R; Corrado, M; Cosenza, A; Ferri, L; Leonardi, F; Buti, S

Dose-dense chemotherapy with Docetaxel, Cisplatin, folinic acid and 5-fluorouracil (TCAF DD) in metastatic gastric cancer (MGC): A feasibility study

2006-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negli, F; Buononato, M; Lazzarelli, S; Brighenti, M; Passalacqua, R

Titolo	Data di pubblicazione	Autore(i)
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A phase II study	1-gen-2007	Chiesa, Md; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Lazzarelli, S; Brighenti, M; Passalacqua, R
Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial	1-gen-2013	Caffo, O; Sava, T; Basso, U; Buti, S; Lo Re, G; Sacco, C; Lodde, M; Facchini, G; Zustovich, F; Perin, A; Russo, L; Veccia, A; Galligioni, E
Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): update of a phase II study	1-gen-2010	Dalla Chiesa, M; Poli, R; Tomasello, G; Lazzarelli, S; Brighenti, M; Negri, F; Curti, A; Auzzani, A; Buti, S; Liguigli, W; Passalacqua, R
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab	1-gen-2018	Mazzaschi, G; Facchinetti, F; Madeddu, D; Buti, S; Gelsomino, F; Ardizzoni, A; Aversa, F; Missale, G; Quaini, F; Tiseo, M
High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with Oxaliplatin, Folinic Acid (FA), 5-Fluorouracil (5-FU) and Irinotecan (COFFI) in metastatic gastric cancer (MGC)	1-gen-2008	Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Brighenti, M; Lazzarelli, S; Auzzani, A; Curti, A; Martinotti, M; Passalacqua, R
A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): A pilot study	1-gen-2012	Buti, S; Donini, M; Lazzarelli, S; Brighenti, M; Passalacqua, R
Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)	1-gen-2017	Procopio, G; Prisciandaro, M; Iacovelli, R; Mancini, M; Fornarini, G; Facchini, G; Carteni, G; Napolitano, M; Sternberg, Cn; Caserta, C; Bregni, M; Massari, F; Buti, S; Biasco, E; De Giorgi, U; Zustovich, F; Ratta, R; Ortega, C; Tortora, G; Verzoni, E
Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A feasibility study	1-gen-2006	Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Lazzarelli, S; Brighenti, M; Donati, G; Cattaneo, M; Passalacqua, R
Gefitinib plus interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)	1-gen-2005	Buti, S; Chiesa, Md; Tomasello, G; Negri, F; Machiavelli, A; Bosio, G; Stifani, I; Betti, M; Buononato, M; Passalacqua, R
LOH as “the missing instability” potentially underlying the tumor immunogenicity: on the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer	1-gen-2017	Bersanelli, M; Gnetti, L; Azzoni, C; Bottarelli, L; Gasparro, D; Leonardi, F; Silini, Em; Buti, S
Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)	1-gen-2015	Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; Di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)	1-gen-2007	Passalacqua, R; Buzio, C; Buti, S; Labianca, R; Porta, C; Boni, C; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Caminiti, C
Relationship between enzalutamide activity and previous antiandrogen withdrawal syndrome (AWS) in patients with metastatic castration-resistant prostate cancer (MCRPC)	1-gen-2015	Alesini, D; Sisani, M; Altavilla, A; Procopio, G; Hamzaj, A; Grillone, F; Massari, F; Marrocolo, F; Zaniboni, A; Mattioli, R; Buti, S; Battaglia, M; Caffo, O; De Angelis, V; Bracarda, S
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient's counselling preliminary analysis of the INVIDIa study	1-gen-2017	Bersanelli, M; Castrignanò, P; Gambale, E; Cortellini, A; Tiseo, M; Natoli, C; Ficorella, C; Panni, S; Rossetti, S; Papa, A; Mazzoni, F; Facchini, G; De Giorgi, U; Procopio, G; Atzori, F; Sava, T; De Luca, E; Maestri, A; Massari, F; Buti, S
Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)	1-gen-2017	Bracarda, S; Galli, L; Maruzzo, M; Lo Re, G; Buti, S; Favaretto, A; Costanzo, Fd; Sacco, C; Merlano, M; Mucciarini, C; Zafarana, E; Romito, S; Maestri, A; Giorgio, Cg; Ionta, Mt; Turci, D; De Giorgi, U; Procopio, G; Cortesi, E; Porta, C
Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets	1-gen-2009	Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Dalla Chiesa, M; Tomasello, G; Negri, F; Lazzarelli, S
Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials	1-gen-2013	Caffo, O; Sava, T; Zustovich, F; Lodde, M; Sacco, C; Lo Re, G; Buti, S; Basso, U; Gamucci, T; Facchini, G; Perin, A; Segati, R; Russo, L; Veccia, A; Galligioni, E
Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)	1-gen-2008	Passalacqua, R; Buti, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Lazzarelli, S
Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors	1-gen-2017	Bersanelli, M; Vaglio, A; Sverzellati, N; Galetti, M; Incerti, M; Parziale, R; Corrado, M; Cosenza, A; Ferri, L; Leonardi, F; Buti, S
Dose-dense chemotherapy with Docetaxel, Cisplatin, folinic acid and 5-fluorouracil (TCAF DD) in metastatic gastric cancer (MGC): A feasibility study	1-gen-2006	Dalla Chiesa, M; Tomasello, G; Buti, S; Negli, F; Buononato, M; Lazzarelli, S; Brighenti, M; Passalacqua, R

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 501 a 520 di 1.822

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext1790
reserved26
open6